Program
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102
Also written as “TQB2102 for injection”, “TQB2102 for Injection” and “TQB2102 Injection”.
In Sino Biopharmaceutical’s pipeline, HER2双抗ADC
. Its studies are mostly in Breast Neoplasms · Biliary Tract Neoplasms · Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung, led by Sino Biopharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 1312 open or running | phase 3since Aug 16, 2024 | Feb 10, 2023 | Jan 2027phase 3 · NCT06561607 |
- Named in Sino Biopharmaceutical’s own pipeline as
TQB2102
, phase 3, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 10, 2023First study: phase 1 study in Advanced CancerFirst studyNCT05735496 · 219 enrolled · China
- Oct 30, 2023Phase 1 study in Breast NeoplasmsNCT06115902 · 153 enrolled · China
- May 22, 2024Phase 2 study in Biliary Tract NeoplasmsNCT06431490 · 102 planned · China
- Jun 6, 2024Phase 2 study in Breast NeoplasmsNCT06452706 · 42 planned · China
- Jul 4, 2024Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06496490 · 270 planned · China
- Aug 16, 2024Phase 3 study in Breast NeoplasmsNCT06561607 · 542 enrolled · China
- Jan 6, 20252 phase 2 studiesNCT06767800, NCT06798207
- May 21, 20252 phase 3 studies in Breast NeoplasmsNCT07003074, NCT07008976
- Jun 20, 2025Phase 3 study in HER2-positive Breast CancerNCT07043725 · 544 planned · China
- Mar 6, 2026Phase 3 study in HER2 IHC3+ Advanced Colorectal CancerNCT07483684 · 142 planned · China
- Mar 25, 2026Phase 2 study in Advanced Solid TumorNCT07512583 · 178 planned · China
Ahead
- Jan 2027Primary completion: phase 3 study in Breast NeoplasmsNCT06561607
- May 2027Primary completion: phase 2 study in Biliary Tract NeoplasmsNCT06431490
- Aug 2027Primary completion: phase 3 study in HER2 IHC3+ Advanced Colorectal CancerNCT07483684
- Sep 2027Primary completion: phase 3 study in HER2-positive Breast CancerNCT07043725
TargetBeta
“HER2双抗ADC”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) ”NCIt, by rule
Other programs on ERBB2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Trastuzumabrule | Hoffmann-La Roche | phase 4 | 85 |
| pertuzumabrule | Hoffmann-La Roche | phase 4 | 56 |
| trastuzumab deruxtecanrule | Daiichi Sankyo | phase 4 | 49 |
| tucatinibrule | Pfizer | phase 4 | 25 |
| disitamab vedotin | RemeGen | phase 3 | 36 |
| trastuzumab rezetecanrule | Jiangsu HengRui Medicine | phase 3 | 36 |
| Lutetium-177 | Novartis | phase 3 | 24 |
| trastuzumab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 21 |
| Gallium-68 | Philogen | phase 3 | 17 |
| zongertinibrule | Boehringer Ingelheim | phase 3 | 15 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| anbenitamab | CSPC Pharmaceutical Group | phase 3 | 12 |
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07512583Advanced Solid Tumor · China | 2 | Recruiting | Mar 2028 | 178 |
| NCT07483684HER2 IHC3+ Advanced Colorectal Cancer · China | 3 | Not yet recruiting | Aug 2027 | 142 |
| NCT07043725HER2-positive Breast Cancer · China | 3 | Recruiting | Sep 2027 | 544 |
| NCT07008976Breast Neoplasms · China | 3 | Recruiting | Mar 2028 | 246 |
| NCT07003074Breast Neoplasms · China | 3 | Recruiting | Jul 2029 | 642 |
| NCT06798207Gynecological Tumors · China | 2 | Recruiting | May 2026 | 170 |
| NCT06767800Gastroesophageal Adenocarcinoma · China | 2 | Recruiting | Sep 2026 | 204 |
| NCT06561607Breast Neoplasms · China | 3 | Active, not recruiting | Jan 2027 | 542 |
| NCT06496490Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Jun 2026 | 270 |
| NCT06452706Breast Neoplasms · China | 2 | Recruiting | Jun 2026 | 42 |
| NCT06431490Biliary Tract Neoplasms · China | 2 | Recruiting | May 2027 | 102 |
| NCT06115902Breast Neoplasms · China | 1 | Completed | Feb 1, 2025 | 153 |
| NCT05735496Advanced Cancer · China | 1 | Active, not recruiting | Jul 21, 2025 | 219 |
How it is read
Names in the registry
- “TQB2102 for injection”, 6 entries
- “TQB2102 for Injection”, 2 entries
- “TQB2102 Injection”, 2 entries
- “TQB2930 injection+TQB2102 for injection”, 1 entry
- “TQB2102 for injection combined with Benmelstobart injection”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 6 studies
- Biliary Tract Neoplasms, 1 study
- Colorectal Neoplasms, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.